REGISTER now for FREE 
|
FREE patent keyword monitoring and additional FREE benefits. REGISTER now for FREE
|
|
|
Drug, Bio-affecting And Body Treating Compositions > Designated Organic Active Ingredient Containing (doai) > Heterocyclic Carbon Compounds Containing A Hetero Ring Having Chalcogen (i.e., O,s,se Or Te) Or Nitrogen As The Only Ring Hetero Atoms Doai > Hetero Ring Is Six-membered Consisting Of One Nitrogen And Five Carbon Atoms > Polycyclo Ring System Having The Six-membered Hetero Ring As One Of The Cyclos > Bicyclo Ring System Having The Six-membered Hetero Ring As One Of The Cyclos > Quinuclidines (including Unsaturation) Quinuclidines (including Unsaturation)Quinuclidines (including Unsaturation) patent applications listed are from June 2005 to current and include Date, Patent Application Number, Patent Title, Patent Abstract summary and are linked to the corresponding patent application page.12/07/06 - 20060276502 - Pharmaceutical use of 1-azabicyclo[2.2.2]octanes and a method of testing compounds for the ability of activating inactive wt p53. The present invention relates to the use of 1-azabicyclo[2.2.2]octanes, capable of transferring wild type p53 from an inactive and non-functional conformation into an active conformation, for the preparation of a pharmaceutical compositions for use in treating medical compositions wherein wt p53 exists in an inactive state defined herein, especially malignant ... 11/23/06 - 20060264458 - Quinine dosage forms and methods of use thereof Disclosed herein are quinine formulations and methods of using quinine formulations. Specifically disclosed are methods of using quinine and informing a user of information, including potential adverse effects, the effect of food on quinine's pharmacokinetics, effect of dosing various strengths of quinine, effect of maximum plasma concentrations of quinine in ... 11/02/06 - 20060247270 - 3-substituted-2(arylalkyl)-1-azabicycloalkanes and methods of use thereof The present invention relates to 3-substituted-2-(arylalkyl)-1-azabicycloalkanes, methods of preparing the compounds and methods of treatment using the compounds. The azabicycloalkanes generally are azabicycloheptanes, azabicyclooctanes, or azabicyclononanes. The aryl group in the arylalkyl moiety is a 5- or 6-membered ring heteroaromatic, preferably 3-pyridinyl and 5-pyrimidinyl moieties, and the alkyl group is ... 09/28/06 - 20060217415 - Novel quinuclidine derivatives and their pharmaceutical use This invention relates to novel quinuclidine derivatives and their use as pharmaceuticals. Due to their pharmacological profile the compounds of the invention may be useful for the treatment of diseases or disorders as diverse as those related to the cholinergic system of the central nervous system (CNS), the peripheral nervous ... 09/14/06 - 20060205770 - Novel salts of quinuclidine derivative There is provided an acid addition salt of (−)-(3R)-quinuclidin-3-yl(1R)-1-phenyl-1,2,3,4-tetrahydroisoquinoline-2-carboxylate with an acid selected from the group consisting of (−)-(2S,3S)-tartaric acid, (+)-(2S,3S)-di-O-benzoyltartaric acid, (+)-(2S,3S)-di-O-(4-methylbenzoyl)tartaric acid, (−)-L-phenylalanine, benzenesulfonic acid, cyclohexanesulfamic acid, hydrobromic acid, naphthalene-2-sulfonic acid, sebacic acid, (+)-camphor-10-sulfonic acid, p-toluenesulfonic acid, ethanesulfonic acid, methanesulfonic acid and methyl phosphate, which has little hygroscopicity ... 08/24/06 - 20060189652 - New heterocyclic compounds, their preparation and their use as medicaments, in particular as anti-bacterial agents The invention also relates to a process for the preparation of these compounds as well as their use as medicaments, in particular as anti-bacterial agents. ... 08/03/06 - 20060173038 - Medicaments for the prevention or treatment of heart failure comprising administration of an anticholinergic The present invention relates to a method for the prevention or the treatment of heart failure comprising administration of a therapeutically effective amount of an anticholinergic 1, medicaments for the prevention or treatment of heart failure comprising one or more, preferably one anticholinergic 1, and methods for the preparation of ... 07/27/06 - 20060167042 - Quinuclidine amide derivatives New quinuclidine amide derivatives having the chemical structure of general formula (I) and pharmaceutically acceptable salts thereof including quaternary salts of formula (II) are disclosed; as well as processes for their preparation, pharmaceutical compositions 10 comprising them and their use in therapy as antagonists of M3 muscarinic receptors. ... 06/15/06 - 20060128749 - Compounds wherein A, D, Ar1, E and Ar2 are as defined in the specification, processes for preparing them, pharmaceutical compositions containing them and their use in therapy, especially in the treatment or prophylaxis of psychotic and intellectual impairment disorders. ... 05/18/06 - 20060106056 - Novel quinuclidine derivatives and medicinal compositions containing the same which shows high affinity for muscarinic M3 receptors (Hm3). ... 05/18/06 - 20060106055 - Novel quinuclidine derivatives and medicinal compositions containing the same which shows high affinity for muscarinic M3 receptors (Hm3). ... 05/04/06 - 20060094751 - Quinuclidine derivatives and pharmaceutical compositions containing the same Carbamates of formula (I) or pharmaceutically acceptable salts thereof, including quaternary ammonium salts of formula (II) are disclosed; as well as processes for their preparation, pharmaceutical compositions comprising them and their use in therapy as antagonists of M3 muscarinic receptors. ... 02/16/06 - 20060035923 - Overactive bladder treating drug A therapeutic agent for overactive bladder containing tamsulosin or a pharmaceutically acceptable salt thereof as an effective ingredient. ... 01/26/06 - 20060019984 - Treatment of diseases with alpha-7nach receptor full agonists The present invention relates to compositions and methods to treat diseases or conditions with alpha-7 nicotinic acetylcholine receptor (AChR) full agonists by decreasing levels of tumor necrosis factor-alpha and/or by stimulating vascular angiogenesis. ... 01/19/06 - 20060014781 - Thiazole, imidazole and oxazole compounds and treatments of disorders associated with protein aging Provided are, among other things, compounds of formula I or IA, ... 11/03/05 - 20050245567 - Novel quinuclidine derivatives and their use This invention relates to novel quinuclidine derivatives and their use as pharmaceuticals. Due to their pharmacological profile the compounds of the invention may be useful for the treatment of diseases or disorders as diverse as those related to the cholinergic system of the central nervous system (CNS), the peripheral nervous ... 10/20/05 - 20050234095 - Indazoles, benzothiazoles, benzoisothiazoles, benzisoxazoles, and preparation and uses thereof The present invention relates generally to the field of ligands for nicotinic acetylcholine receptors (nACh receptors), activation of nACh receptors, and the treatment of disease conditions associated with defective or malfunctioning nicotinic acetylcholine receptors, especially of the brain. Further, this invention relates to novel compounds (e.g., indazoles and benzothiazoles), which ... 09/22/05 - 20050209273 - Metabotropic glutamate receptor antagonists The present invention concerns compounds of formula. In a preferable embodiment, X represents O; R1 represents C1-4alkyl; cycloC3-12alkyl or (cycloC3-12alkyl)C1-6alkyl, wherein one or more hydrogen atoms in a C1-6alkyl-moiety or in a cycloC3-12alkyl-moiety optionally may be replaced by C1-6alkyloxy, aryl, halo or thienyl; R2 represents hydrogen; halo; C1-6alkyl or amino; ... 09/22/05 - 20050209272 - Novel quinuclidine derivatives and medicinal compositions containing the same which shows high affinity for muscarinic M3 receptors (Hm3). ... 09/22/05 - 20050209271 - Form of renzapride hydrochloride hydrate and uses thereof The present invention provides a novel crystal form of renzapride hydrochloride hydrate. The invention further provides methods of preparing the same and uses thereof. ... 09/15/05 - 20050203125 - Pharmaceutical compositions comprising dextromethorphan and quinidine for the treatment of neurological disorders Pharmaceutical compositions and methods for treating neurological disorders by administering same are provided. The compositions comprise dextromethorphan in combination with quinidine. ... 08/11/05 - 20050176757 - Stereoisomeric compounds and methods for the treatment of gastrointestinal and central nervous system disorders wherein the variables are as defined herein, and compositions for the safe and effective treatment of various gastrointestinal disorders including, but not limited to, gastroparesis, gastroesophageal reflux and related conditions. The compounds of the subject invention are also useful in treating a variety of conditions involving the central nervous system. ... 08/11/05 - 20050176756 - 3-substituted quinuclidines and their use This invention relates to novel 3-substituted quinuclidine derivatives, which are found to be cholinergic ligands at the nicotinic acetylcholine receptors and modulators of the monoamine receptors and transporters. Due to their pharmacological profile the compounds of the invention may be useful for the treatment of diseases or disorders as diverse ... 07/14/05 - 20050154010 - Treatment of cancer with mefloquine, its purified enantiomers, and mefloquine analogs Cancers, particularly solid tumors (e.g., breast, lung, renal, colon and ovarian cancers and melanomas) and cancers of the hematologic system, e.g., hemopoietic cancers such as leukemias, lymphomas or myelomas, are treated by administration of a therapeutically effective amount of a compound having the formula (1): (I)in which the quinoline ring ... 06/23/05 - 20050137226 - 3-quinuclidinyl heteroatom bridged biaryl derivatives or pharmaceutically acceptable salts, esters, amides, or prodrugs thereof, wherein: A and G are each independently N or N+—O−; m and n are each independently 0, 1, or 2; X1 and X3 are each independently O, S, and —N(R1)—; X2 is O, S, —N(R1)—, —N(Ar2)—, and —N(R2)C(O)—; Ar1 is a ... ### FreshPatents.com Support |